Axsome Therapeutics Files 8-K on Financial Condition & Other Events
Ticker: AXSM · Form: 8-K · Filed: Jan 4, 2024 · CIK: 1579428
| Field | Detail |
|---|---|
| Company | Axsome Therapeutics, INC. (AXSM) |
| Form Type | 8-K |
| Filed Date | Jan 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-condition, corporate-update, 8-K
TL;DR
**Axsome Therapeutics just filed an 8-K, expect financial updates and other news soon.**
AI Summary
Axsome Therapeutics, Inc. filed an 8-K on January 4, 2024, to report on "Results of Operations and Financial Condition" and "Other Events." This filing indicates that the company is providing an update on its financial performance and other significant developments, though the specific details of these results and events are not contained within this particular filing. For investors, this matters because it signals that important financial and operational information is being disclosed, which could impact the company's stock price and future outlook.
Why It Matters
This 8-K signals that Axsome Therapeutics is updating the market on its financial health and other key developments, which could influence investor sentiment and stock valuation.
Risk Assessment
Risk Level: low — This 8-K is a procedural filing indicating an upcoming disclosure, not a disclosure of specific negative events, thus posing low immediate risk.
Analyst Insight
A smart investor would monitor for subsequent filings or press releases from Axsome Therapeutics that provide the actual details of the 'Results of Operations and Financial Condition' and 'Other Events' mentioned in this 8-K, as those will contain the actionable information.
Key Players & Entities
- Axsome Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 04, 2024 (date) — date of earliest event reported and filing date
- 001-37635 (other) — Commission File Number for Axsome Therapeutics
- AXSM (other) — trading symbol for Axsome Therapeutics Common Stock
- Nasdaq Global Market (other) — exchange where Axsome Therapeutics Common Stock is registered
FAQ
What is the purpose of this 8-K filing by Axsome Therapeutics, Inc.?
This 8-K filing by Axsome Therapeutics, Inc. is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically reporting on "Results of Operations and Financial Condition" and "Other Events" as of January 04, 2024.
When was the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is January 04, 2024.
What is Axsome Therapeutics, Inc.'s trading symbol and on which exchange is its common stock registered?
Axsome Therapeutics, Inc.'s trading symbol is AXSM, and its Common Stock, Par Value $0.0001 Per Share, is registered on the Nasdaq Global Market.
What is the business address and phone number of Axsome Therapeutics, Inc. as stated in the filing?
The business address of Axsome Therapeutics, Inc. is One World Trade Center, 22nd Floor, New York, New York 10007, and its telephone number is (212) 332-3241.
Does this 8-K filing contain the detailed financial results or specific information about the 'Other Events'?
No, this 8-K filing only indicates the categories of information being reported (Results of Operations and Financial Condition, Other Events) but does not contain the detailed financial results or specific information about those events within the provided text.
Filing Stats: 602 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-01-04 07:11:55
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share AXSM Nasdaq Global Market
Filing Documents
- axsm-20240104.htm (8-K) — 40KB
- axsm-ex99_1.htm (EX-99.1) — 104KB
- img36028404_0.jpg (GRAPHIC) — 22KB
- 0000950170-24-001488.txt ( ) — 299KB
- axsm-20240104.xsd (EX-101.SCH) — 2KB
- axsm-20240104_lab.xml (EX-101.LAB) — 12KB
- axsm-20240104_pre.xml (EX-101.PRE) — 9KB
- axsm-20240104_htm.xml (XML) — 4KB
02 Results of Operations and Financial Conditions
Item 2.02 Results of Operations and Financial Conditions. On January 4, 2024, Axsome Therapeutics, Inc. (the “Company”) issued a press release entitled “Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones.” For purposes of this Item 2.02, the Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
01 Other Events
Item 8.01 Other Events. As reported above, on January 4, 2024, the Company issued a press release entitled “Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones.” For purposes of this Item 8.01, the full text of the press release is also being filed as Exhibit 99.1 hereto, and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated January 4, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Axsome Therapeutics, Inc. Date: January 4, 2024 By: /s/ Herriot Tabuteau, M.D. Name: Title: Herriot Tabuteau, M.D. President and Chief Executive Officer